Stockholders' Equity and Stock-Based Compensation (Tables)
|
12 Months Ended |
Dec. 31, 2018 |
Stockholders Equity And Stock-based Compensation |
|
Schedule of Warrants Outstanding |
|
|
December
31, |
|
|
December
31, |
|
Outstanding
Warrants |
|
2018 |
|
|
2017 |
|
Issued
to Investors on October 25, 2013, entitling the holders to purchase 250,000 common shares in the Company at an exercise price
of $11.50 per common share up to and including April 24, 2021. In 2016, 59,450 of these warrants were exchanged for common
stock, and all remaining warrant holders agreed to new warrant terms, which excluded any potential net cash settlement provisions
in exchange for a reduced exercise price of $6.25 per share. |
|
|
163,986 |
|
|
|
163,986 |
|
|
|
|
|
|
|
|
|
|
Issued
to Investors on November 17, 2014, entitling the holders to purchase 546,919 common shares in the Company at an exercise price
of $11.55 per common share up to and including May 16, 2022. On June 30, 2016, the warrant holders agreed to new warrant terms,
which excluded any potential net cash settlement provisions in order to classify them as equity in exchange for a reduced
exercise price of $6.25 per share. |
|
|
546,919 |
|
|
|
546,919 |
|
|
|
|
|
|
|
|
|
|
Issued
to an investor on August 10, 2016, entitling the holders to purchase 500,000 common shares in the Company at an exercise price
of price of $0.01 per share, up to and including December 31, 2019. These warrants were exercised in January 2018. |
|
|
— |
|
|
|
500,000 |
|
|
|
|
|
|
|
|
|
|
Issued
to an investment bank and subsequently transferred to a principal of the investment bank regarding the Series B Preferred
Stock investment on January 30, 2018, entitling the holder to purchase 133,432 common shares in the Company at an exercise
price of $1.50 per share, up to and including January 30, 2021. |
|
|
133,432 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
Total |
|
|
844,337 |
|
|
|
1,210,905 |
|
|
Schedule of Share-based Compensation, Stock Options, Activity |
|
|
Year
ended
December
31,
|
|
|
|
2018 |
|
|
2017 |
|
Research
and development expenses |
|
$ |
965,617 |
|
|
$ |
504,913 |
|
General
and administrative expenses |
|
|
1,414,288 |
|
|
|
688,393 |
|
Total
stock-based compensation expense |
|
$ |
2,379,905 |
|
|
$ |
1,193,306 |
|
|
Schedule of weighted average years remaining of expected life activity |
Expected
volatility |
|
|
90 |
% |
Risk
free interest rate |
|
|
2.84 |
% |
Dividend
yield rate |
|
|
0 |
% |
Weighted
average years |
|
9.8 months
|
|
Closing
price per share – common stock |
|
$ |
0.88 |
|
|
Schedule of Stock option transactions of the employees |
Stock
option transactions of the employees, directors, and consultants are summarized as follows for the year ended December 31, 2018:
|
|
Options
Outstanding
|
|
|
Weighted
Average
Exercise
Price
|
|
|
Weighted
Average
Grant
Date
Fair
Value
|
|
Beginning
of the year |
|
|
3,976,884 |
|
|
$ |
3.58 |
|
|
$ |
2.49 |
|
Granted
|
|
|
1,784,455 |
|
|
|
0.90 |
|
|
|
0.70 |
|
Exercised
|
|
|
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(143,980 |
) |
|
|
1.10 |
|
|
|
0.83 |
|
Expired
|
|
|
(13,205 |
) |
|
|
30.60 |
|
|
|
21.13 |
|
End
of the year |
|
|
5,604,154 |
|
|
$ |
2.72 |
|
|
$ |
1.96 |
|
Options
exercisable |
|
|
3,935,138 |
|
|
$ |
3.50 |
|
|
$ |
2.49 |
|
Stock
option transactions of the employees, directors, and consultants are summarized as follows for the year ended December 31, 2017:
|
|
Options
Outstanding
|
|
|
Weighted
Average
Exercise
Price
|
|
|
Weighted
Average
Grant
Date
Fair
Value
|
|
Beginning
of the year |
|
|
2,172,581 |
|
|
$ |
6.70 |
|
|
$ |
4.83 |
|
Granted
|
|
|
1,854,277 |
|
|
|
1.05 |
|
|
|
0.77 |
|
Exercised
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Forfeited
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Expired
|
|
|
(49,974 |
) |
|
|
45.53 |
|
|
|
38.70 |
|
End
of the year |
|
|
3,976,884 |
|
|
$ |
3.58 |
|
|
$ |
2.49 |
|
Options
exercisable |
|
|
2,434,148 |
|
|
$ |
4.84 |
|
|
$ |
3.36 |
|
|
Schedule of Non-Vested Options, Activity |
|
|
Shares |
|
|
Weighted-
Average
Fair
Value
Grant
Date
|
|
|
Weighted
Average
Exercise
Price
|
|
Non-vested
– December 31, 2016 |
|
|
450,476 |
|
|
$ |
3.60 |
|
|
$ |
5.40 |
|
Granted
|
|
|
1,854,277 |
|
|
|
0.77 |
|
|
|
1.05 |
|
Vested
|
|
|
(762,017 |
) |
|
|
1.67 |
|
|
|
2.54 |
|
Forfeited
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Non-vested
– December 31, 2017 |
|
|
1,542,736 |
|
|
$ |
1.10 |
|
|
$ |
1.58 |
|
Granted
|
|
|
1,784,455 |
|
|
|
0.70 |
|
|
|
0.90 |
|
Vested
|
|
|
(1,514,195 |
) |
|
$ |
1.27 |
|
|
$ |
1.58 |
|
Forfeited
|
|
|
(143,980 |
) |
|
|
0.83 |
|
|
|
1.10 |
|
Non-vested
– December 31, 2018 |
|
|
1,669,016 |
|
|
$ |
0.54 |
|
|
$ |
0.91 |
|
|
Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award |
The
following table provides certain information with respect to the above-referenced stock options that were outstanding and exercisable
at December 31, 2018:
|
|
|
Stock
Options Outstanding |
|
|
Stock
Options Vested |
|
|
|
|
Weighted |
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
|
|
|
Average |
|
|
|
|
|
|
|
|
Average |
|
|
|
|
|
|
|
|
|
|
Remaining |
|
|
|
|
|
Weighted |
|
|
Remaining |
|
|
|
|
|
Weighted |
|
|
|
|
Contractual |
|
|
Number |
|
|
Average |
|
|
Contractual |
|
|
Number |
|
|
Average |
|
|
|
|
Life |
|
|
of |
|
|
Exercise |
|
|
Life |
|
|
of |
|
|
Exercise |
|
|
Exercise
Prices |
|
-Years |
|
|
Awards |
|
|
Price |
|
|
-Years |
|
|
Awards |
|
|
Price |
|
$ |
0.90-$1.04 |
|
|
9.60 |
|
|
|
1,616,402 |
|
|
$ |
0.90 |
|
|
|
— |
|
|
|
0 |
|
|
$ |
— |
|
$ |
1.05-$2.00 |
|
|
8.57 |
|
|
|
2,560,330 |
|
|
$ |
1.18 |
|
|
|
8.56 |
|
|
|
2,507,716 |
|
|
$ |
1.18 |
|
$ |
2.01-$6.00 |
|
|
6.86 |
|
|
|
813,583 |
|
|
$ |
4.59 |
|
|
|
6.86 |
|
|
|
813,583 |
|
|
$ |
4.59 |
|
$ |
6.01-$20.00 |
|
|
4.16 |
|
|
|
501,334 |
|
|
$ |
7.48 |
|
|
|
4.16 |
|
|
|
501,334 |
|
|
$ |
7.48 |
|
$ |
20.01-$43.25 |
|
|
0.72 |
|
|
|
112,505 |
|
|
$ |
29.46 |
|
|
|
0.72 |
|
|
|
112,505 |
|
|
$ |
29.46 |
|
|
Total |
|
|
8.07 |
|
|
|
5,604,154 |
|
|
$ |
2.72 |
|
|
|
7.42 |
|
|
|
3,935,138 |
|
|
$ |
3.50 |
|
The
following table provides certain information with respect to the above-referenced stock options that were outstanding and exercisable
at December 31, 2017:
|
|
|
Stock
Options Outstanding |
|
|
Stock
Options Vested |
|
|
|
|
Weighted |
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
|
|
|
Average |
|
|
|
|
|
|
|
|
Average |
|
|
|
|
|
|
|
|
|
|
Remaining |
|
|
|
|
|
Weighted |
|
|
Remaining |
|
|
|
|
|
Weighted |
|
|
|
|
Contractual |
|
|
Number |
|
|
Average |
|
|
Contractual |
|
|
Number |
|
|
Average |
|
|
|
|
Life |
|
|
of |
|
|
Exercise |
|
|
Life |
|
|
of |
|
|
Exercise |
|
Exercise
Prices |
|
-Years |
|
|
Awards |
|
|
Price |
|
|
-Years |
|
|
Awards |
|
|
Price |
|
$ |
1.05-$2.00 |
|
|
9.56 |
|
|
|
2,528,666 |
|
|
$ |
1.18 |
|
|
|
9.28 |
|
|
|
1,197,708 |
|
|
$ |
1.33 |
|
$ |
2.01-$6.00 |
|
|
7.86 |
|
|
|
821,174 |
|
|
$ |
4.59 |
|
|
|
7.86 |
|
|
|
651,429 |
|
|
$ |
4.58 |
|
$ |
6.01-$20.00
|
|
|
5.12 |
|
|
|
505,694 |
|
|
$ |
7.47 |
|
|
|
4.93 |
|
|
|
463,661 |
|
|
$ |
7.58 |
|
$ |
20.01-$45.00
|
|
|
1.66 |
|
|
|
118,016 |
|
|
$ |
29.85 |
|
|
|
1.66 |
|
|
|
118,016 |
|
|
$ |
29.85 |
|
$ |
45.01-$72.00
|
|
|
0.18 |
|
|
|
3,334 |
|
|
$ |
50.25 |
|
|
|
0.18 |
|
|
|
3,334 |
|
|
$ |
50.25 |
|
|
Total
|
|
|
8.40 |
|
|
|
3,976,884 |
|
|
$ |
3.58 |
|
|
|
7.70 |
|
|
|
2,434,148 |
|
|
$ |
4.84 |
|
|
Schedule of Service-based Payment Award, Stock Options, Valuation Assumptions |
Weighted
average assumptions used in the Black Scholes option-pricing model for the years ended December 31, 2018 and 2017, were as follows:
|
|
Year
ended |
|
|
Year
ended |
|
|
|
December
31, |
|
|
December
31, |
|
|
|
2018 |
|
|
2017 |
|
Average
risk-free interest rate |
|
|
2.79 |
% |
|
|
2.15 |
% |
Average
expected life- years |
|
|
6.0 |
|
|
|
5.67 |
|
Expected
volatility |
|
|
90.11 |
% |
|
|
87.24 |
% |
Expected
dividends |
|
|
0.0 |
% |
|
|
0.0 |
% |
In
accordance with ASC 718, the market-based and performance-based long-term non-qualified option grants awards issued in 2017 were
assigned a fair value of $0.80 per option share (total value of $0.9 million) on the date of grant using a Monte Carlo simulation.
The following assumptions were used in the Monte Carlo simulation model:
Expected volatility
|
|
87.5%
to 91 |
% |
Risk free interest
rate |
|
2.24%
to 2.42 |
|
Dividend
yield rate |
|
|
0 |
% |
Weighted
average remaining expected life |
|
4.2 years |
|
Closing
price per share – common stock |
|
$ |
1.05 |
|
|